LENZ Therapeutics, Inc. - Common Stock, par value $0.00001 per share (LENZ)

CUSIP: 52635N103

Q3 2025 13F Holders as of 30 Sep 2025

Holder snapshot 7 signals
Share change
+4,411,875
Put/Call ratio
327%
SEC-reported price per share
$46.58
Number of holders
166
Value change
+$224,909,861
Number of buys
121
Open additional details 1 more signal available
Number of sells
26
Security identity Names, identifiers, and filing context for this profile. 1 source field
Shares outstanding
31,441,412

Security key

52635N103

Report period

Q3 2025

Institutions

166

Top holders

10

Ownership snapshot

Top reported holders of LENZ - LENZ Therapeutics, Inc. - Common Stock, par value $0.00001 per share (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
Point72 Asset Management,...
Disclosed value leader
RA CAPITAL MANAGEMENT, L.P.
Comparable rows
15/15
Latest evidence
30 Sep 2025
13D/G 13F 3/4/5 Lead comparable stake: 4.8% 13D/G row: Point72 Asset Management, L.P. Showing 1-6 of 15 holder rows.

Quick read

Point72 Asset Management, L.P. leads the comparable SEC ownership view at 4.8%.

15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens Point72 Asset Management, L.P.'s linked filing trail.
Comparable ownership Top 5
Point72 Asset Management, L.P. 4.8%
Paradigm Biocapital Advisors LP 3.8%
Versant Venture Capital VI, L.P. 5.8%
RA CAPITAL MANAGEMENT, L.P. 13%
Alpha Wave Global, LP 11%

Ownership % is shown only when SEC disclosures are safely comparable across share classes.

Detailed SEC evidence table Showing 1-6 of 15 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
Point72 Asset Management, L.P.
13D/G 13F
Steven A. Cohen · Company
4.8%
$63,244,042
1,357,751 shares
$0 30 Sep 2025
Paradigm Biocapital Advisors LP
13F 13D/G
Company
3.8%
from 13D/G
$50,327,204
1,717,066 shares
30 Jun 2025
Versant Venture Capital VI, L.P.
3/4/5
10%+ Owner
5.8%
$85,316,256
1,814,726 shares
-$33,745,537 30 Sep 2025
RA CAPITAL MANAGEMENT, L.P.
13F
Company
13F
13%
$122,481,302
4,178,823 shares
30 Jun 2025
Alpha Wave Global, LP
13F
Company
13F
11%
$105,873,904
3,612,211 shares
30 Jun 2025
BlackRock, Inc.
13F
Company
13F
4.6%
$41,985,440
1,432,461 shares
30 Jun 2025
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q3 2025

Investor-level positions for this CUSIP, loaded as an interactive table.

Institutions
166
Shares
29,140,610
Rows available
166
Investor Option Weight % Change % SEC-reported value * Price Shares Share Change Activity Report Period

* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Compare Q3 2025 vs Q2 2025 Across Filers

Q2 2025 holders
113
Q3 2025 holders
166
Holder diff
53
Investor Q2 2025 Shares Q3 2025 Shares Share Diff Share Chg % Q2 2025 value Q3 2025 value Value change Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .